UY34456A - Anticuerpos anti-il-36r - Google Patents

Anticuerpos anti-il-36r

Info

Publication number
UY34456A
UY34456A UY0001034456A UY34456A UY34456A UY 34456 A UY34456 A UY 34456A UY 0001034456 A UY0001034456 A UY 0001034456A UY 34456 A UY34456 A UY 34456A UY 34456 A UY34456 A UY 34456A
Authority
UY
Uruguay
Prior art keywords
antibodies
escanear
figuras
escanear figuras
Prior art date
Application number
UY0001034456A
Other languages
English (en)
Inventor
Canada Keith
Su-Ellen Brown
Chlewicki Lukasz
Howell Michael
Mennerich Detlev
Joseph Robert Woska Jr
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34456(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY34456A publication Critical patent/UY34456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de unión anti-IL-36R, en particular nuevos anticuerpos anti-IL-36R y métodos diagnósticos y terapéuticos y composiciones para utilizar los mismos.
UY0001034456A 2011-11-16 2012-11-16 Anticuerpos anti-il-36r UY34456A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
UY34456A true UY34456A (es) 2013-05-31

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034456A UY34456A (es) 2011-11-16 2012-11-16 Anticuerpos anti-il-36r

Country Status (39)

Country Link
US (3) US9023995B2 (es)
EP (2) EP3536710A1 (es)
JP (3) JP6289375B2 (es)
KR (3) KR20200110476A (es)
CN (5) CN112812183B (es)
AP (1) AP2014007571A0 (es)
AR (1) AR089178A1 (es)
AU (1) AU2012339734B2 (es)
BR (1) BR112014011594B1 (es)
CA (1) CA2852994C (es)
CL (1) CL2014001123A1 (es)
CO (1) CO7020871A2 (es)
CY (2) CY1122278T1 (es)
DK (1) DK2780373T3 (es)
EA (1) EA031948B1 (es)
EC (1) ECSP14004976A (es)
ES (1) ES2755732T3 (es)
FI (1) FIC20230020I1 (es)
FR (1) FR23C1023I2 (es)
HR (1) HRP20191835T1 (es)
HU (2) HUE047437T2 (es)
IL (2) IL232100B (es)
LT (2) LT2780373T (es)
MX (1) MX347164B (es)
MY (1) MY195289A (es)
NL (1) NL301233I2 (es)
NO (1) NO2023024I1 (es)
PE (1) PE20142041A1 (es)
PH (1) PH12014501108B1 (es)
PL (1) PL2780373T3 (es)
PT (1) PT2780373T (es)
RS (1) RS59248B1 (es)
SG (1) SG11201402283PA (es)
SI (1) SI2780373T1 (es)
TW (1) TWI573804B (es)
UA (1) UA115540C2 (es)
UY (1) UY34456A (es)
WO (1) WO2013074569A1 (es)
ZA (1) ZA201402491B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
EA031948B1 (ru) 2011-11-16 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
CU24481B1 (es) * 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
US10526410B2 (en) * 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
US10723793B2 (en) * 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CA3087701A1 (en) * 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
MX2020009544A (es) * 2018-03-14 2020-10-05 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.
EP4183804A1 (en) * 2018-03-14 2023-05-24 Boehringer Ingelheim International GmbH Use of il-36r antibodies for treatment of inflammatory bowel disease
US11589562B2 (en) * 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
JP7386224B2 (ja) * 2018-07-16 2023-11-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｉｌ３６ｒ抗体
US20220267454A1 (en) 2018-08-16 2022-08-25 Cantargia Ab Anti-IL1RAP Antibody Compositions
TW202019958A (zh) * 2018-09-28 2020-06-01 日商協和麒麟股份有限公司 Il-36抗體及其用途
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
JP2022515480A (ja) * 2018-12-27 2022-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体
CA3132917A1 (en) 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
JPWO2021112196A1 (es) * 2019-12-05 2021-06-10
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
WO2021236496A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of atopic dermatitis
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
AU2021319103A1 (en) 2020-07-30 2023-02-09 Anaptysbio, Inc. Anti-interleukin 36 receptor (IL-36r) therapy for ichthyosis
MX2023003723A (es) 2020-09-30 2023-04-24 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
EP4289863A1 (en) * 2020-12-17 2023-12-13 Shanghai Huaota Biopharmaceutical Co., Ltd. Bispecific antibody targeting il-17a and il-36r and application thereof
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
AU2022231135A1 (en) 2021-03-04 2023-07-27 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
EP4334356A1 (en) * 2021-05-03 2024-03-13 Boehringer Ingelheim International Gmbh Method for producing spesolimab
WO2022262828A1 (zh) * 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 抗il-36r抗体及其用途
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
US20230049147A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
EP4409592A2 (en) 2021-09-28 2024-08-07 Boehringer Ingelheim International Gmbh System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation
US11802149B2 (en) * 2021-10-28 2023-10-31 Abbvie Inc. Anti-amyloid beta antibodies and methods of using the same
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
US20240301074A1 (en) 2023-03-09 2024-09-12 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for the treatment of hidradentitis suppurativa (hs)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
JPH08500826A (ja) 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE69836082T2 (de) 1997-08-01 2007-05-10 Schering Corp. Membranproteine aus säugetierzellen; verwandte reagentien
EP1272647B1 (en) * 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
AU2003282667A1 (en) * 2002-10-03 2004-04-23 Large Scale Biology Corporation Multimeric protein engineering
MY169746A (en) * 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2444418A3 (en) * 2006-09-08 2012-08-08 Amgen, Inc IL-1 Family Variants
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
CN101802011A (zh) 2007-06-29 2010-08-11 先灵公司 Mdl-1应用
JP2012501184A (ja) 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用
EA031948B1 (ru) 2011-11-16 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)

Also Published As

Publication number Publication date
PL2780373T3 (pl) 2020-03-31
JP2020156506A (ja) 2020-10-01
TWI573804B (zh) 2017-03-11
EA031948B1 (ru) 2019-03-29
WO2013074569A1 (en) 2013-05-23
US20130236471A1 (en) 2013-09-12
BR112014011594A2 (pt) 2017-07-04
IL272035A (en) 2020-02-27
EP3536710A1 (en) 2019-09-11
FR23C1023I1 (fr) 2023-07-21
US10550189B2 (en) 2020-02-04
SG11201402283PA (en) 2014-06-27
US20170298135A9 (en) 2017-10-19
JP2018093885A (ja) 2018-06-21
FR23C1023I2 (fr) 2024-03-29
MY195289A (en) 2023-01-12
EA201400579A1 (ru) 2014-10-30
MX347164B (es) 2017-04-18
US9023995B2 (en) 2015-05-05
EP2780373B1 (en) 2019-08-21
NL301233I1 (es) 2023-06-07
BR112014011594B1 (pt) 2021-11-09
AU2012339734B2 (en) 2017-02-16
EP2780373A1 (en) 2014-09-24
AU2012339734A1 (en) 2014-04-24
JP2015500633A (ja) 2015-01-08
CA2852994C (en) 2023-02-14
NO2023024I1 (no) 2023-05-30
AR089178A1 (es) 2014-08-06
UA115540C2 (uk) 2017-11-27
KR20200110476A (ko) 2020-09-23
DK2780373T3 (da) 2019-11-04
PT2780373T (pt) 2019-11-27
CY1122278T1 (el) 2020-11-25
KR102159109B1 (ko) 2020-09-23
CN118515766A (zh) 2024-08-20
CN104080808A (zh) 2014-10-01
CN107007833B (zh) 2020-12-11
KR20190122877A (ko) 2019-10-30
CN104080808B (zh) 2016-11-16
IL232100B (en) 2020-04-30
ECSP14004976A (es) 2015-11-30
JP6719490B2 (ja) 2020-07-08
CY2023014I2 (el) 2023-11-15
PE20142041A1 (es) 2014-12-18
FIC20230020I1 (fi) 2023-06-01
SI2780373T1 (sl) 2019-12-31
US20150203584A1 (en) 2015-07-23
MX2014005759A (es) 2014-09-08
NL301233I2 (nl) 2023-09-13
JP6289375B2 (ja) 2018-03-07
CO7020871A2 (es) 2014-08-11
LT2780373T (lt) 2019-09-25
TW201333037A (zh) 2013-08-16
CN107007833A (zh) 2017-08-04
ZA201402491B (en) 2021-09-29
CL2014001123A1 (es) 2015-01-23
IL232100A0 (en) 2014-05-28
KR102038310B1 (ko) 2019-11-01
CY2023014I1 (el) 2023-11-15
CA2852994A1 (en) 2013-05-23
CN112812183A (zh) 2021-05-18
KR20140101738A (ko) 2014-08-20
RS59248B1 (sr) 2019-10-31
HRP20191835T1 (hr) 2019-12-27
LTPA2023518I1 (es) 2023-06-12
AP2014007571A0 (en) 2014-04-30
CN118496365A (zh) 2024-08-16
NZ623425A (en) 2015-12-24
PH12014501108A1 (en) 2014-08-04
HUE047437T2 (hu) 2020-04-28
HUS2300021I1 (hu) 2023-07-28
ES2755732T3 (es) 2020-04-23
CN112812183B (zh) 2024-06-11
PH12014501108B1 (en) 2014-08-04
US20200231684A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
UY34456A (es) Anticuerpos anti-il-36r
UY34206A (es) Anticuerpo monoclonal de interleucina-31
CO7151521A2 (es) Anticuerpos anti-fcrn
UY34582A (es) Anticuerpos anti-cxcr3
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34836A (es) Nuevo organismos
UY4169Q (es) Altoparlante
BR112013028512A2 (pt) cápsula
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34654A (es) Inhibidores de la beta-secretasa
BR112014001219A2 (pt) perfume
UY4153Q (es) Batería
BR112013028251A2 (pt) polipeptídeo
CL2011002403S1 (es) Luminaria solar.
UY34483A (es) Polipeptido
BR112014027219A2 (pt) método
ITMI20121619A1 (it) Proiettore.
CL2009001973S1 (es) Mostrador.
UY4152Q (es) Batería
CL2012001192S1 (es) Botella.
UY34501A (es) ?procedimiento de purificación de factor viii?.
UY33996A (es) Preparacion sólida
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي
CL2011000572S1 (es) Contenedor.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20220408